The EmblemHealth Preauthorization List has been updated to include Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan); a new FDA-approved radiopharmaceutical used for treatment of progressive, prostate-specific membrane antigen (PSMA)-positive, metastatic, castration-resistant prostate cancer.
The ConnectiCare Medicare Preauthorization List was updated to remove the preauthorization requirements for home-care services using HCPCS Codes H1000, H1002, H1003, and H1005 for dates of service starting Jan. 1, 2022.
Reminder: Starting Nov. 1, 2022, CPT Codes 64628 and 64629 related to spinal surgery will require preauthorization for ConnectiCare’s Medicare members.
